Dupilumab in a patient with severe asthma and glucocorticoid hypersensitivity: a case report

Recently, several biologics have been approved for the treatment of severe asthma. Dupilumab, a biologic used to treat severe asthma, is a monoclonal antibody targeting interleukin-4 and interleukin-13. In the present case, inhaled corticosteroid-induced glucocorticoid hypersensitivity was suspected, and the administration of omalizumab and mepolizumab had no beneficial effects. Subsequently, we switched to dupilumab therapy, which produced better effectiveness. Therefore, when a biologic agent proves ineffective, changing to another suitable biologic agent should be considered.

Automated summary

Recently, several biologics have been approved for the treatment of severe asthma. One of these biologics, dupilumab, is a monoclonal antibody targeting interleukin-4 and interleukin-13. In a specific case, dupilumab was found to be more effective compared to omalizumab and mepolizumab in a patient suspected of having inhaled corticosteroid-induced glucocorticoid hypersensitivity. Therefore, considering a switch to another suitable biologic agent is recommended when one proves ineffective.